RU2715642C2 - АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА - Google Patents

АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА Download PDF

Info

Publication number
RU2715642C2
RU2715642C2 RU2017118262A RU2017118262A RU2715642C2 RU 2715642 C2 RU2715642 C2 RU 2715642C2 RU 2017118262 A RU2017118262 A RU 2017118262A RU 2017118262 A RU2017118262 A RU 2017118262A RU 2715642 C2 RU2715642 C2 RU 2715642C2
Authority
RU
Russia
Prior art keywords
antibody
seq
cell
ser
ptprs
Prior art date
Application number
RU2017118262A
Other languages
English (en)
Russian (ru)
Other versions
RU2017118262A3 (enExample
RU2017118262A (ru
Inventor
Томохиде ЯМАЗАКИ
Цзин ЧЖАО
Кодзи ИСИДА
Ясуе СИБАТА
Минквон Чо
Маюки ЭНДО
Original Assignee
ЭсБиАй БАЙОТЕК КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭсБиАй БАЙОТЕК КО., ЛТД. filed Critical ЭсБиАй БАЙОТЕК КО., ЛТД.
Publication of RU2017118262A3 publication Critical patent/RU2017118262A3/ru
Publication of RU2017118262A publication Critical patent/RU2017118262A/ru
Application granted granted Critical
Publication of RU2715642C2 publication Critical patent/RU2715642C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
RU2017118262A 2011-04-28 2012-04-27 АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА RU2715642C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-101752 2011-04-28
JP2011101752 2011-04-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013152816/10A Division RU2013152816A (ru) 2011-04-28 2012-04-27 АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА

Publications (3)

Publication Number Publication Date
RU2017118262A3 RU2017118262A3 (enExample) 2018-11-02
RU2017118262A RU2017118262A (ru) 2018-11-02
RU2715642C2 true RU2715642C2 (ru) 2020-03-02

Family

ID=46147004

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017118262A RU2715642C2 (ru) 2011-04-28 2012-04-27 АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА
RU2013152816/10A RU2013152816A (ru) 2011-04-28 2012-04-27 АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013152816/10A RU2013152816A (ru) 2011-04-28 2012-04-27 АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА

Country Status (16)

Country Link
US (2) US9803026B2 (enExample)
EP (2) EP3232202B1 (enExample)
JP (2) JP6001557B2 (enExample)
KR (1) KR101873614B1 (enExample)
CN (1) CN103703372B (enExample)
AU (2) AU2012248158C1 (enExample)
CA (1) CA2834243C (enExample)
ES (2) ES2638088T3 (enExample)
HU (2) HUE054211T2 (enExample)
IL (1) IL229127A (enExample)
MX (1) MX352599B (enExample)
PL (2) PL3232202T3 (enExample)
PT (2) PT2702412T (enExample)
RU (2) RU2715642C2 (enExample)
SG (3) SG10202108240VA (enExample)
WO (1) WO2012148003A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
WO2012148003A1 (en) * 2011-04-28 2012-11-01 Sbi Biotech Co., Ltd. ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
CN104854132A (zh) 2012-07-13 2015-08-19 昂考梅德药品有限公司 Rspo3结合剂及其用途
ES2817897T3 (es) * 2012-07-23 2021-04-08 La Jolla Inst Allergy & Immunology PTPRS y proteoglicanos en enfermedad autoinmune
US11160873B2 (en) * 2014-02-04 2021-11-02 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
EP3102940B1 (en) * 2014-02-04 2019-06-26 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
WO2016044295A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
BR112017011170A2 (pt) * 2014-12-18 2018-02-27 Hoffmann La Roche método para determinar a citotoxicidade dependente do complemento de uma composição
MX2019011252A (es) * 2017-03-23 2020-01-23 Univ Pennsylvania Anticuerpos anti-c5a y usos de los mismos.
EP3599843A4 (en) * 2017-03-24 2021-01-13 The Regents of the University of California PROTEOGLYCAN IRREGULARITIES IN ABNORMAL FIBROBLASTS AND THERAPIES BASED ON THEM
US11242398B2 (en) 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members
EP4037712A4 (en) 2019-10-04 2023-11-01 Albert Einstein College of Medicine KIR3DL3 IS AN IMMUNE SYSTEM INHIBITANT RECEPTOR AND USES THEREOF
CA3225321A1 (en) 2021-07-30 2023-02-02 Nunzio Bottini Ptprs in autoimmunity
CN114426582B (zh) * 2022-01-07 2022-11-25 陕西脉元生物科技有限公司 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用
CN116041526B (zh) * 2022-11-14 2023-09-29 华中农业大学 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
EP4676980A2 (en) * 2023-03-03 2026-01-14 Case Western Reserve University Cell adhesion molecule targeted immunotherapies
CN117050170A (zh) * 2023-08-16 2023-11-14 武汉生物制品研究所有限责任公司 靶向识别白喉毒素的中和单克隆抗体8h6及其应用
CN118994384B (zh) * 2024-08-09 2025-09-26 陕西脉元生物科技有限公司 抗Ri的人源化单克隆抗体及其应用和基于其的检测方法
CN119874900B (zh) * 2025-03-06 2025-10-17 吉林大学 一种单克隆抗体及其在制备治疗肿瘤药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009656A1 (en) * 1993-10-01 1995-04-13 New York University Novel receptor-type phosphotyrosine phosphatase-sigma
WO2007041317A2 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
RU2312109C2 (ru) * 2003-03-14 2007-12-10 Тайсо Фармасьютикал Ко., Лтд. Моноклональное антитело и продуцирующая его гибридома
WO2010056332A1 (en) * 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2011097327A2 (en) * 2010-02-02 2011-08-11 La Jolla Institute For Allergy & Immunology Compositions and methods of modulating receptor protein tyrosine phosphatases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013325A1 (ja) 2002-08-01 2004-02-12 Ginkgo Biomedical Research Institute Co., Ltd. マウスインターフェロン産生細胞の検出方法
CA2561073C (en) 2004-03-27 2014-01-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2009003274A1 (en) * 2007-06-29 2009-01-08 The Hospital For Sick Children Susceptibility gene for inflammatory bowel disease
US20120231014A1 (en) * 2009-08-18 2012-09-13 Case Western Reserve University Neural Regeneration
WO2012148003A1 (en) * 2011-04-28 2012-11-01 Sbi Biotech Co., Ltd. ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009656A1 (en) * 1993-10-01 1995-04-13 New York University Novel receptor-type phosphotyrosine phosphatase-sigma
RU2312109C2 (ru) * 2003-03-14 2007-12-10 Тайсо Фармасьютикал Ко., Лтд. Моноклональное антитело и продуцирующая его гибридома
WO2007041317A2 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
WO2010056332A1 (en) * 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2011097327A2 (en) * 2010-02-02 2011-08-11 La Jolla Institute For Allergy & Immunology Compositions and methods of modulating receptor protein tyrosine phosphatases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WO 2010056332 A1 A1 20.05.2010. *

Also Published As

Publication number Publication date
SG10202108240VA (en) 2021-09-29
ES2788183T3 (es) 2020-10-20
PL3232202T3 (pl) 2020-10-05
RU2017118262A3 (enExample) 2018-11-02
KR101873614B1 (ko) 2018-07-02
US10730955B2 (en) 2020-08-04
PT3232202T (pt) 2020-05-22
EP2702412A1 (en) 2014-03-05
AU2016262677A1 (en) 2016-12-08
WO2012148003A1 (en) 2012-11-01
AU2012248158B2 (en) 2016-09-08
CN103703372B (zh) 2018-01-26
KR20140033024A (ko) 2014-03-17
AU2012248158C1 (en) 2017-02-02
AU2016262677B2 (en) 2018-08-30
CA2834243A1 (en) 2012-11-01
JP6412072B2 (ja) 2018-10-24
BR112013027631A2 (pt) 2022-01-04
IL229127A0 (en) 2013-12-31
HUE034752T2 (en) 2018-02-28
MX2013012393A (es) 2014-04-30
ES2638088T3 (es) 2017-10-18
JP2017048183A (ja) 2017-03-09
EP3232202A1 (en) 2017-10-18
MX352599B (es) 2017-11-30
US9803026B2 (en) 2017-10-31
US20140127223A1 (en) 2014-05-08
IL229127A (en) 2017-11-30
EP2702412B1 (en) 2017-07-26
JP2014524733A (ja) 2014-09-25
RU2013152816A (ru) 2015-06-10
US20180155446A1 (en) 2018-06-07
HUE054211T2 (hu) 2021-08-30
PT2702412T (pt) 2017-11-02
EP3232202B1 (en) 2020-02-19
SG194614A1 (en) 2013-12-30
SG10201503257WA (en) 2015-06-29
PL2702412T3 (pl) 2018-01-31
CA2834243C (en) 2019-08-27
JP6001557B2 (ja) 2016-10-05
CN103703372A (zh) 2014-04-02
RU2017118262A (ru) 2018-11-02
AU2012248158A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
KR101873614B1 (ko) 항인간 수용체형 단백질 티로신 포스파타아제 σ 항체
KR102384845B1 (ko) 항-pd-l1 항체 및 그의 용도
CN106715471B (zh) 抗cd127的抗体
CN101952426B (zh) 抗bst2抗体
KR101860280B1 (ko) 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
TWI654201B (zh) Ｐｄ－１抗體、其抗原結合片段及其醫藥用途
CN110776566B (zh) 抗ilt7抗体
KR20170064550A (ko) 인간화 항-ox40 항체 및 이의 용도
BRPI0713086A2 (pt) diagnóstico e tratamento de cáncer usando anticorpo anti-desmogleìna-3
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
KR20210018807A (ko) 인간-유래 항-(폴리-ga) 디펩타이드 반복 (dpr) 항체
JP2016514690A (ja) 抗ｃｄ２５抗体およびそれらの使用
CN114685660A (zh) 抗cldn18.2抗体及其制备方法和应用
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
CN114437227A (zh) 双特异抗体及其应用
CN113135994B (zh) 一种激活型抗ox40抗体、生产方法及应用
KR20210055722A (ko) 신규 항체 및 뉴클레오티드 서열 및 이의 용도
CN115466329B (zh) 一种抗pd-1人源化抗体及其应用
RU2812910C2 (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28
HK40076013A (en) Anti-cldn18.2 antibody, and preparation method and use thereof
HK40073393A (en) Bispecific antibody and use thereof
HK40058119A (en) Development and application of immune cell activator
HK40074348A (zh) 抗tigit抗体及其应用
HK1153502B (en) Anti-bst2 antibody
KR20080099231A (ko) 항체 억제 인자 ⅷ에 대해 유도된 세포 독성 항체